Deferiprone
| 證據等級: L5 | 預測適應症: 9 個 |
目錄
Deferiprone: From Iron Overload (Thalassemia) to Hepatic Porphyria
One-Sentence Summary
Deferiprone is an oral iron chelator whose established clinical role — noted in the evidence pack's own rationale — is managing chronic iron overload from long-term transfusion (e.g., thalassemia major). The TxGNN model predicts it may be effective for Hepatic Porphyria, but this direction is currently supported only by 2 preclinical/animal publications and no registered clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Iron overload (chronic, transfusion-related — per evidence pack rationale; not marketed locally, so no formal approved-indication text is available) |
| Predicted New Indication | Hepatic Porphyria |
| TxGNN Prediction Score | 99.20% |
| Evidence Level | L4 |
| Finland Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on the information present in this evidence pack, deferiprone is an oral iron-chelating agent, and its rationale entries indicate proven efficacy in reducing iron-catalyzed oxidative damage in transfusion-dependent iron overload states.
Mechanistically, hepatic porphyria and iron overload intersect through iron-driven oxidative stress: excess free iron catalyzes Fenton-type reactions that worsen porphyrin accumulation and associated hemolysis. Two preclinical studies in the evidence pack support this link — one showing iron chelation rescues hemolytic anemia and skin photosensitivity in a congenital erythropoietic porphyria model (PMID 32678895), and another showing an oral iron chelator (deferiprone) reduces uroporphyrin accumulation in a murine model of porphyria cutanea tarda (PMID 17854053).
However, both supporting studies are animal/preclinical in nature, with no human clinical trial or observational data identified. The mechanistic plausibility is reasonable, but translation to human hepatic porphyria remains unconfirmed.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32678895 | 2020 | Preclinical/Animal | Blood | Iron chelation rescued hemolytic anemia and skin photosensitivity in a congenital erythropoietic porphyria (CEP) model, linked to reduced porphyrin isomer I overload |
| 17854053 | 2007 | Preclinical/Animal (murine) | Hepatology (Baltimore, Md.) | Oral iron chelator (deferiprone/L1) reduced hepatic uroporphyrin accumulation in Hfe(-/-) mice, comparable to iron-deficient diet approach for porphyria cutanea tarda |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for the hepatic porphyria indication is limited to two preclinical/animal studies (L4) with no clinical trials or human data; the drug is also not currently marketed locally, and core safety documentation (TFDA warnings/contraindications, MOA) is flagged as a blocking data gap in this evidence pack.
To proceed, the following is needed:
- Confirmed mechanism of action (MOA) data from DrugBank or primary literature (DG002)
- TFDA/local package insert data on warnings and contraindications before any S1 safety evaluation (DG001)
- Human clinical evidence (case series, observational, or trial data) in hepatic porphyria patients before advancing beyond a research-question stage
- Note: within this same evidence pack, beta-thalassemia with other manifestations (rank 8, L3, "Proceed with Guardrails") has materially stronger literature support and may be a more actionable near-term candidate than hepatic porphyria
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.